At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rescuing OSA Patients Unable to Tolerate CPAP Using Endotype-Targeted Combination Drug Therapy: a Randomized, Double-Blind, Placebo-Controlled Trial
In Brief
A Phase 2 clinical trial evaluating Acetazolamide, Eszopiclone, and 2 other interventions for OSA and Obstructive Sleep Apnea. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
Obstructive sleep apnea (OSA) is common and associated with many adverse health consequences, but many patients are unable to tolerate standard therapies such as continuous positive airway pressure (CPAP) and thus remain untreated. Single-drug therapies have shown promising results in treating sleep apnea, but on average patients have only experienced partial relief. Multi-drug therapy may offer a more effective treatment approach. The goal of this study is to test the effect of combination therapy with three FDA-approved drugs (Diamox \[acetazolamide\], Lunesta \[eszopiclone\] +/- Effexor \[venlafaxine\]) on OSA severity and physiology.
Study Details
Timeline
Interventions
Acetazolamide tablet (encapsulated)
Eszopiclone tablet (encapsulated)
Sugar capsule manufactured to match encapsulated Acetazolamide/Eszopiclone
Venlafaxine capsule